Impact of fibromyalgia and LLDAS/remission state at baseline on PROs
| FM yes | FM no | P value | LLDAS/Rem yes | LLDAS/Rem no | P value | |
| SF-36 PCS | 41.1±9.5 | 48.6±9.7 | <0.0001 | 47.9±10.2 | 45.5±9 | 0.14 |
| SF-36 MCS | 38.3±10.5 | 44.7±11.8 | <0.01 | 44.1±12.3 | 41.9±9.3 | 0.27 |
| FACIT | 30±11.3 | 39.4±9.4 | <0.0001 | 38.1±10.4 | 36.7±10.2 | 0.43 |
| LIT | 39.4±22 | 23.7±20.1 | <0.001 | 25.4±21.4 | 30.4±20.7 | 0.18 |
| HADS-A | 8.1±3.8 | 6.5±3.9 | 0.07 | 6.5±4 | 7.7±3.7 | 0.1 |
| HADS-D | 7.7±3 | 4.9±3.6 | <0.001 | 5.1±3.5 | 6.3±4 | 0.08 |
Bold values represent statistically significant values.
FACIT, Functional Assessment of Chronic Illness Therapy; FM, fibromyalgia; HADS-A, Hospital Anxiety and Depression Scale for anxiety; HADS-D, Hospital Anxiety and Depression Scale for depression; LIT, Lupus Impact Tracker; LLDAS, Lupus Low Disease Activity State; PROs, Patient-Reported Outcomes; SF-36 MCS, Short Form 36 mental component summary; SF-36 PCS, Short Form 36 physical component summary.